Biopharmaceutic Classification System: A Scientific Framework for Pharmacokinetic Optimization in Drug Research
The DOI matches its Crossref record.
Abstract
The tenets of biopharmaceutics, solubility and permeability, are of pivotal importance in new drug discovery and lead optimization due to the dependence of drug absorption and pharmacokinetics on these two properties. A classification system for drugs based on these two fundamental parameters, Biopharmaceutic Classification System (BCS), provides drug designer an opportunity to manipulate structure or physicochemical properties of lead candidates so as to achieve better "deliverability". Considering the facts for failure of NCEs, drug research, once concentrating on optimizing the efficacy and safety of the leads, dramatically transformed in the past two decades. With the enormous number of molecules being synthesized using combinatorial and parallel synthesis, high throughput methodologies for screening solubility and permeability has gained significant interest in pharmaceutical industry. Ultimate aim of the drug discovery scientist in pharmacokinetic optimization is to tailor the molecules so that they show the features of BCS class I without compromising on pharmacodynamics. Considerations to optimize drug delivery and pharmacokinetics right from the initial stages of drug design propelled need for "High Throughput Pharmaceutics" (HTP). In silico predictions and development of theoretical profiles for solubility and lipophilicity provides structure based biopharmaceutical optimization, while in vitro experimental models (microtitre plate assays and cell cultures) validate the predictions. Thus, biopharmaceutical characterization during drug design and early development helps in early withdrawal of molecules with insurmountable developmental problems associated with pharmacokinetic optimization.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although immunotherapy is often applied parenterally, the oral administration route is preferred due to higher compliance of patients and lower complication rates [1].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [1]
In the citing paper
“Its main advantage over subcutaneous injections is the painless application resulting in a higher patient compliance [1].”
From Characterization of Vibrio cholerae neuraminidase as an immunomodulator for novel formulation of oral allergy immunotherapy (2018) · cites this paper as [1]
Citations
Cites
Still being checked.
Cited by
Items 101–119 of 119
Mass Transfer Phenomena and Biological Membranes
Zakeri‐Milani, P., & Valizadeh, H. (2011) · InTech eBooks · doi:10.5772/15162
Solubilizzazione di farmaci di classe II e di classe IV mediante polossameri
Vietti, B. (2009) · DSpaceUnipr (University of Parma)
Koninck, P. D. (2009) · Archipel (Université du Québec à Montréal)
Improving the Biopharmaceutical Properties of Cyclic Opioid Peptide Prodrugs
Nofsinger, R. (2008) · KU ScholarWorks (University of Kansas)
Multifunctional combinatorial-designed nanoparticles for nucleic acid therapy
Amiji, M. M. (2016) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2224764
Lead Identification/Optimization
Wong, M., & McAllister, M. S. (2017) · Wiley eBooks · doi:10.1002/9781118907894.ch2
Larregieu, C. A. (2014) · eScholarship (California Digital Library)
Impact of Influx Transporters on Drug Absorption
El‐Kattan, A. F. (2017) · Wiley eBooks · doi:10.1002/9781118916926.ch7
(2014) · CRC Press eBooks · doi:10.1201/b17582-28
Zinnia, M. A., & Islam, A. B. M. M. K. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230223120829
Sousa, I. M. D. O. (2019) · doi:10.47749/t/unicamp.2019.1157158
Artificial intelligence and accelerated computing in drug discovery: an updated overview
Niazi, S. K., & Mariam, Z. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34059-8.00020-8
Anwer, R., Ullah, I., Khan, A., Mir, M. A., Bashir, N., Shah, S. U. A., & Ayaz, M. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02177-7
Satapathy, T., & Sahu, P. (2026) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2026.100866
Manikandan, K. L. R. (2024) · Frontiers in Health Informatics
Metadata
- Authors
- Varma, M., Khandavilli, S., Ashokraj, Y., Jain, A., Dhanikula, A., Sood, A., Thomas, N., Pillai, O., Sharma, P., Gandhi, R., Agrawal, S., Nair, V., & Panchagnula, R.
- Affiliations
- National Institute of Pharmaceutical Education and Research (IN)
- Corresponding author
- Panchagnula, Ramesh
- Venue
- Current Drug Metabolism
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-10-01
- Volume
- 5
- Issue
- 5
- Pages
- 375-388
- ISSN
- 1389-2002 (ISSN-L)
- OpenAlex
- W2001958300
- Cited by
- 107
- References
- 0
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 4 · 2013: 6 · 2012: 9
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Drug Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- solubility, permeability, drug absorption, pharmacokinetic optimization, lead optimization, new chemical entities, high-throughput screening, lipophilicity prediction, structure-based drug design, in vitro permeability model
- MeSH terms
- Animals, Biopharmaceutics, Chemistry, Pharmaceutical, Pharmaceutical Preparations, Humans, Intestinal Absorption, Pharmacokinetics, Pharmacology, Clinical, Research, Solubility
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.